Takeda To Build On COVID-19 Awareness For Its Dengue Vaccine
TAK-003 Could Be Blockbuster
Takeda’s vaccines chief Rajeev Venkayya tells Scrip about its COVID-19 vaccines partnerships, and how the pandemic can stimulate action against other infectious disease threats such as Dengue.
You may also be interested in...
Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.
The VC firm is making the most of a surge of capital from new and established investors who believe in the promise of European biopharma start-ups.
Immunogenicity data from Valneva’s COV-COMPARE study are encouraging, but the inactivated vaccine will need proper efficacy data to gain a toehold in a crowded market.